UNICYCIVE THERAPEUTICS, INC. Proceeds from License Fees Received
UNICYCIVE THERAPEUTICS, INC. (UNCY) reported Proceeds from License Fees Received of $700 for the 3-month period ending 2023-12-31, per its 10-K filed 2024-03-28.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromLicenseFeesReceived · last filed 2025-03-31
- UNICYCIVE THERAPEUTICS, INC. proceeds from license fees received for the quarter ending 2023-12-31 was $700.00.
- UNICYCIVE THERAPEUTICS, INC. proceeds from license fees received for the quarter ending 2023-09-30 was $0.00.
- UNICYCIVE THERAPEUTICS, INC. proceeds from license fees received for the quarter ending 2023-06-30 was $0.00.
- UNICYCIVE THERAPEUTICS, INC. proceeds from license fees received for the quarter ending 2023-03-31 was $675.00M.
- UNICYCIVE THERAPEUTICS, INC. proceeds from license fees received for fiscal 2023 was $700.00K, a 30.00% decline from fiscal 2022.
- UNICYCIVE THERAPEUTICS, INC. proceeds from license fees received for fiscal 2022 was $1.00M.
| Period end | Proceeds from License Fees Received 3 month | Proceeds from License Fees Received 3 month as first filed | Proceeds from License Fees Received 6 month | Proceeds from License Fees Received 9 month | Proceeds from License Fees Received 9 month as first filed | Proceeds from License Fees Received 12 month |
|---|---|---|---|---|---|---|
| 2023-12-31 | $700.00 10-K · filed 2024-03-28 | $700.00 derived: sum of 2 quarters · filed 2024-03-28 | $700.00 derived: sum of 3 quarters · filed 2024-08-14 | $700.00K 10-K · filed 2025-03-31 | ||
| 2023-09-30 | $0.00 10-Q · filed 2023-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-08-14 | $675.00K 10-Q · filed 2024-11-13 | $675.00M 10-Q · filed 2023-11-14 | ||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $675.00M 10-Q · filed 2024-08-14 | ||||
| 2023-03-31 | $675.00M 10-Q · filed 2024-05-13 | $675.00K 10-Q · filed 2023-05-16 | ||||
| 2022-12-31 | $1.00M 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |